{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:14:09Z","timestamp":1786634049830,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF). Despite advances in disease-modifying therapy, the mainstay of treatment for congestion\u2014loop diuretics\u2014has remained largely unchanged for 50 years. In these two articles (part I: loop diuretics and part II: combination therapy), we will review the history of diuretic treatment and current trial evidence for different diuretic strategies and explore potential future directions of research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>We will assess recent trials, including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF, and assess how these may influence current practice and future research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>There are few data on which to base diuretic therapy in clinical practice. The most robust evidence is for high-dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF, yet this is not reflected in guidelines. There is an urgent need for more and better research on different diuretic strategies in patients with HF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-024-00644-2","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:02:08Z","timestamp":1706785328000},"page":"115-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions\u2014Part II: Combination Therapy"],"prefix":"10.1007","volume":"21","author":[{"given":"Cuthbert","family":"J.J","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleland","family":"J.G.F","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"A.L","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"31","key":"644_CR33","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","volume":"44","author":"SE Yeoh","year":"2023","unstructured":"Yeoh SE, Osmanska J, Petrie MC, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J. 2023;44(31):2966\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehad341. DAPA-RESIST trial comparing dapagliflozin to metolazone in patients treated with high dose IV loop diuretics with diuretic resistance\u00a0","journal-title":"Eur Heart J."},{"issue":"9","key":"644_CR34","first-page":"977","volume":"5","author":"SA Doggrell","year":"2004","unstructured":"Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs. 2004;5(9):977\u201383.","journal-title":"Curr Opin Investig Drugs"},{"key":"644_CR35","doi-asserted-by":"crossref","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332\u201343.","DOI":"10.1001\/jama.297.12.1332"},{"issue":"11","key":"644_CR36","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","volume":"69","author":"GM Felker","year":"2017","unstructured":"Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O\u2019Connor CM. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399\u2013406.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"644_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","volume":"8","author":"ZL Cox","year":"2020","unstructured":"Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail. 2020;8(3):157\u201368. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.012.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"644_CR38","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297(12):1332\u201343. https:\/\/doi.org\/10.1001\/jama.297.12.1332.","journal-title":"JAMA"},{"issue":"3","key":"644_CR39","doi-asserted-by":"crossref","first-page":"F207","DOI":"10.1152\/ajpcell.1982.242.3.C207","volume":"242","author":"AI Katz","year":"1982","unstructured":"Katz AI. Renal Na-K-ATPase: its role in tubular sodium and potassium transport. Am J Physiol. 1982;242(3):F207\u201319.","journal-title":"Am J Physiol"},{"issue":"6","key":"644_CR40","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1152\/ajplegacy.1972.222.6.1398","volume":"222","author":"J Torretti","year":"1972","unstructured":"Torretti J, Hendler E, Weinstein E, Longnecker RE, Epstein FH. Functional significance of Na- K-ATPase in the kidney: effects of ouabain inhibition. Am J Physiol. 1972;222(6):1398\u2013405. https:\/\/doi.org\/10.1152\/ajplegacy.1972.222.6.1398.","journal-title":"Am J Physiol"},{"issue":"3","key":"644_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/0002-9343(83)90346-7","volume":"75","author":"AB Covit","year":"1983","unstructured":"Covit AB, Schaer GL, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med. 1983;75(3):445\u20137. https:\/\/doi.org\/10.1016\/0002-9343(83)90346-7.","journal-title":"Am J Med"},{"issue":"3","key":"644_CR42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.HYP.18.3.316","volume":"18","author":"MB Pamnani","year":"1991","unstructured":"Pamnani MB, Chen S, Bryant HJ, et al. Effects of three sodium-potassium adenosine triphosphatase inhibitors. Hypertension. 1991;18(3):316\u201324.","journal-title":"Hypertension"},{"issue":"4","key":"644_CR43","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-n","volume":"22","author":"BF Uretsky","year":"1993","unstructured":"Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22(4):955\u201362. https:\/\/doi.org\/10.1016\/0735-1097(93)90403-n.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"644_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199307013290101","volume":"329","author":"M Packer","year":"1993","unstructured":"Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. Radiance Study N Engl J Med. 1993;329(1):1\u20137. https:\/\/doi.org\/10.1056\/NEJM199307013290101.","journal-title":"Radiance Study N Engl J Med"},{"issue":"1","key":"644_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s0735-1097(97)00133-2","volume":"30","author":"KF Adams Jr","year":"1997","unstructured":"Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol. 1997;30(1):42\u20138. https:\/\/doi.org\/10.1016\/s0735-1097(97)00133-2.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"644_CR46","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/eurjhf\/hft010","volume":"15","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551\u20139. https:\/\/doi.org\/10.1093\/eurjhf\/hft010.","journal-title":"Eur J Heart Fail"},{"key":"644_CR47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-07-0455","volume":"157","author":"BR Walker","year":"2007","unstructured":"Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157:545\u201359.","journal-title":"Eur J Endocrinol"},{"key":"644_CR48","unstructured":"National Institute for Health and Care Excellence. British National Formulary. Prednisolone. Available from: https:\/\/bnf.nice.org.uk\/drugs\/prednisolone"},{"issue":"3","key":"644_CR49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0029-1210971","volume":"95","author":"P Damjancic","year":"1990","unstructured":"Damjancic P, Vierhapper H. Permissive action of glucocorticoid substitution therapy on the effects of atrial natriuretic peptide (hANP) in patients with adrenocortical insufficiency. Exp Clin Endocrinol. 1990;95(3):315\u201321.","journal-title":"Exp Clin Endocrinol"},{"issue":"2","key":"644_CR50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/0006-291X(85)91311-7","volume":"131","author":"R Garcia","year":"1985","unstructured":"Garcia R, Debinski W, Gutkowska J, et al. Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochem Biophys Res Commun. 1985;131(2):806\u201314.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"644_CR51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/jpet.111.184796","volume":"339","author":"C Liu","year":"2011","unstructured":"Liu C, Chen Y, Kang Y, et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure. J Pharmacol Exp Ther. 2011;339(1):203\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"644_CR52","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-2999(90)94800-D","volume":"178","author":"KL Lanier-Smith","year":"1990","unstructured":"Lanier-Smith KL, Currie MG. Effect of glucocorticoids on the binding of atrial natriuretic peptide to endothelial cells. Eur J Pharmacol. 1990;178(1):105\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"644_CR53","doi-asserted-by":"crossref","first-page":"e15607","DOI":"10.1371\/journal.pone.0015607","volume":"5","author":"C Liu","year":"2010","unstructured":"Liu C, Guan J, Kang Y, et al. Inhibition of dehydration-induced water intake by glucocorticoids is associated with activation of hypothalamic natriuretic peptide receptor-A in rat. PLoS ONE. 2010;5(12):e15607.","journal-title":"PLoS ONE"},{"issue":"1 Pt 2","key":"644_CR54","first-page":"I118","volume":"75","author":"J Genest","year":"1987","unstructured":"Genest J, Cantin M. Atrial natriuretic factor. Circulation. 1987;75(1 Pt 2):I118\u201324.","journal-title":"Circulation"},{"issue":"2","key":"644_CR55","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1152\/physrev.1997.77.2.465","volume":"77","author":"J Gutkowska","year":"1997","unstructured":"Gutkowska J, Antunes-Rodrigues J, McCann SM. Atrial natriuretic peptide in brain and pituitary gland. Physiol Rev. 1997;77(2):465\u2013515.","journal-title":"Physiol Rev"},{"issue":"6","key":"644_CR56","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI106937","volume":"51","author":"RD Brown","year":"1972","unstructured":"Brown RD, Strott CA, Liddle GW. Site of stimulation of aldosterone biosynthesis by angiotensin and potassium. J Clin Invest. 1972;51(6):1413\u20138. https:\/\/doi.org\/10.1172\/JCI106937.","journal-title":"J Clin Invest"},{"issue":"2","key":"644_CR57","first-page":"F166","volume":"234","author":"C Baylis","year":"1978","unstructured":"Baylis C, Brenner BM. Mechanism of the glucocorticoid-induced increase in glomerular filtration rate. Am J Physiol. 1978;234(2):F166\u201370.","journal-title":"Am J Physiol"},{"issue":"4","key":"644_CR58","first-page":"320","volume":"10","author":"C Baylis","year":"1990","unstructured":"Baylis C, Handa RK, Sorkin M. Glucocorticoids and control of glomerular filtration rate. Semin Nephrol. 1990;10(4):320\u20139.","journal-title":"Semin Nephrol"},{"issue":"4","key":"644_CR59","first-page":"R1125","volume":"276","author":"R de Matteo","year":"1999","unstructured":"de Matteo R, May CN. Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilatation in sheep. Am J Physiol. 1999;276(4):R1125\u201331.","journal-title":"Am J Physiol"},{"issue":"6","key":"644_CR60","doi-asserted-by":"crossref","first-page":"R1972","DOI":"10.1152\/ajpcell.1997.273.6.C1972","volume":"273","author":"R De Matteo","year":"1997","unstructured":"De Matteo R, May CN. Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide. Am J Physiol. 1997;273(6):R1972\u20139.","journal-title":"Am J Physiol"},{"issue":"1","key":"644_CR61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.24.1.49","volume":"24","author":"JA Bednarik","year":"1994","unstructured":"Bednarik JA, May CN. Differential regional hemodynamic effects of corticotropin in conscious sheep. Hypertension. 1994;24(1):49\u201355.","journal-title":"Hypertension"},{"issue":"3","key":"644_CR62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(99)00121-1","volume":"370","author":"JA Aguirre","year":"1999","unstructured":"Aguirre JA, Ibarra FR, Barontini M, Arrizurieta EE, Armando I. Effect of glucocorticoids on renal dopamine production. Eur J Pharmacol. 1999;370(3):271\u20138.","journal-title":"Eur J Pharmacol"},{"key":"644_CR63","doi-asserted-by":"publisher","unstructured":"Massari F, Mastropasqua F, Iacoviello M, Nuzzolese V, Torres D, Parrinello G. The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde?. Am J Emerg Med. 2012;30(3). https:\/\/doi.org\/10.1016\/j.ajem.2011.01.023","DOI":"10.1016\/j.ajem.2011.01.023"},{"issue":"11","key":"644_CR64","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0828-282X(07)70840-1","volume":"23","author":"C Liu","year":"2007","unstructured":"Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol. 2007;23(11):865\u20138.","journal-title":"Can J Cardiol"},{"issue":"5","key":"644_CR65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1536\/ihj.49.587","volume":"49","author":"H Zhang","year":"2008","unstructured":"Zhang H, Liu C, Ji Z, et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J. 2008;49(5):587\u201395.","journal-title":"Int Heart J"},{"issue":"4","key":"644_CR66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.fjc.0000245242.57088.5b","volume":"48","author":"C Liu","year":"2006","unstructured":"Liu C, Chen H, Zhou C, et al. Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol. 2006;48(4):173\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"644_CR67","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/FJC.0000000000000048","volume":"63","author":"Liu C, Liu K; COPE-ADHF Study Group","year":"2014","unstructured":"Liu C, Liu K; COPE-ADHF Study Group. Cardiac outcome prevention effectiveness of glucocorticoids in acute decompensated heart failure: COPE-ADHF study. J Cardiovasc Pharmacol. 2014;63(4):333\u20138.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"9","key":"644_CR68","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cjca.2012.11.008","volume":"29","author":"C Liu","year":"2013","unstructured":"Liu C, Zhao Q, Zhen Y, et al. Prednisone in uric acid lowering in symptomatic heart failure patients with hyperuricemia (PUSH-PATH) study. Can J Cardiol. 2013;29(9):1048\u201354. https:\/\/doi.org\/10.1016\/j.cjca.2012.11.008.","journal-title":"Can J Cardiol"},{"issue":"5","key":"644_CR69","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1476-5381.2008.00047.x","volume":"156","author":"PW Hadoke","year":"2009","unstructured":"Hadoke PW, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol. 2009;156(5):689\u2013712.","journal-title":"Br J Pharmacol"},{"key":"644_CR70","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/eurheartj\/ehad195","volume":"25","author":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;25:195. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"2","key":"644_CR71","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ejhf.212","volume":"17","author":"WL Miller","year":"2015","unstructured":"Miller WL, Borgeson DD, Grantham JA, Luchner A, Redfield MM, Burnett JC Jr. Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. Eur J Heart Fail. 2015;17(2):144\u201350.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"644_CR72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchf.2015.08.007","volume":"4","author":"R Doukky","year":"2016","unstructured":"Doukky R, Avery E, Mangla A, et al. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail. 2016;4(1):24\u201335.","journal-title":"JACC Heart Fail"},{"issue":"10333","key":"644_CR73","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0140-6736(22)00369-5","volume":"399","author":"JA Ezekowitz","year":"2022","unstructured":"Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial [published correction appears in Lancet. Lancet. 2022;399(10333):1391\u2013400.","journal-title":"Lancet"},{"issue":"12","key":"644_CR74","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamainternmed.2013.552","volume":"173","author":"GB Aliti","year":"2013","unstructured":"Aliti GB, Rabelo ER, Clausell N, Rohde LE, Biolo A, Beck-da-Silva L. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med. 2013;173(12):1058\u201364.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"644_CR75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijcard.2014.03.020","volume":"173","author":"S Gandhi","year":"2014","unstructured":"Gandhi S, Mosleh W, Myers RB. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol. 2014;173(2):139\u201345.","journal-title":"Int J Cardiol"},{"key":"644_CR76","first-page":"6562017","volume":"2016","author":"M Maleki","year":"2016","unstructured":"Maleki M, Nematbakhsh M. Renal blood flow response to angiotensin 1\u20137 versus hypertonic sodium chloride 7.5% administration after acute hemorrhagic shock in rats. Int J Vasc Med. 2016;2016:6562017.","journal-title":"Int J Vasc Med"},{"issue":"2","key":"644_CR77","first-page":"109","volume":"35","author":"ND Kien","year":"1991","unstructured":"Kien ND, Reitan JA, White DA, Wu CH, Eisele JH. Cardiac contractility and blood flow distribution following resuscitation with 7.5% hypertonic saline in anesthetized dogs. Circ Shock. 1991;35(2):109\u201316.","journal-title":"Circ Shock"},{"issue":"10","key":"644_CR78","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1097\/00003246-199910000-00014","volume":"27","author":"D Sirieix","year":"1999","unstructured":"Sirieix D, Hongnat JM, Delayance S, et al. Comparison of the acute hemodynamic effects of hypertonic or colloid infusions immediately after mitral valve repair. Crit Care Med. 1999;27(10):2159\u201365. https:\/\/doi.org\/10.1097\/00003246-199910000-00014.","journal-title":"Crit Care Med"},{"issue":"2\u20133","key":"644_CR79","first-page":"385","volume":"1","author":"MB Vaklotton","year":"1982","unstructured":"Vaklotton MB, Davison JM, Riondel AM, Lindheimer MD. Response of the renin-aldosterone system and antidiuretic hormone to oral water loading and hypertonic saline infusion during and after pregnancy. Clin Exp Hypertens B. 1982;1(2\u20133):385\u2013400.","journal-title":"Clin Exp Hypertens B"},{"issue":"12","key":"644_CR80","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.jacc.2005.01.059","volume":"45","author":"S Paterna","year":"2005","unstructured":"Paterna S, Di Pasquale P, Parrinello G, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005;45(12):1997\u20132003. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.059.","journal-title":"J Am Coll Cardiol"},{"key":"644_CR81","doi-asserted-by":"publisher","unstructured":"DiNicolantonio JJ, Di Pasquale P, Taylor RS, Hackam DG. Heart. Retraction. Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis. Heart. Published Online First: 21 August 2012. 2023; https:\/\/doi.org\/10.1136\/heartjnl-2012-302337","DOI":"10.1136\/heartjnl-2012-302337"},{"issue":"7","key":"644_CR82","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cardfail.2013.05.015","volume":"19","author":"GS Francis","year":"2013","unstructured":"Francis GS. Notice of concern. J Card Fail. 2013;19(7):523. https:\/\/doi.org\/10.1016\/j.cardfail.2013.05.015.","journal-title":"J Card Fail"},{"issue":"3","key":"644_CR83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jchf.2019.10.012","volume":"8","author":"M Griffin","year":"2020","unstructured":"Griffin M, Soufer A, Goljo E, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure: A U.S. Center\u2019s Experience. JACC Heart Fail. 2020;8(3):199\u2013208. https:\/\/doi.org\/10.1016\/j.jchf.2019.10.012.","journal-title":"JACC Heart Fail."},{"issue":"2","key":"644_CR84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.amjms.2023.04.025","volume":"366","author":"J Madieh","year":"2023","unstructured":"Madieh J, Hasan B, Khamayseh I, et al. The safety of intravenous peripheral administration of 3% hypertonic saline: a systematic review and meta-analysis. Am J Med Sci. 2023;366(2):135\u201342.","journal-title":"Am J Med Sci"},{"key":"644_CR85","unstructured":"National Institute for Health and Care Excellence. Acute heart hailure: diagnosis and management. Clinical guideline [CG187]. November 2021. Available from: https:\/\/www.nice.org.uk\/guidance\/cg187 [accessed 1\/7\/2022]"},{"key":"644_CR86","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ejhf.890","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. ESC heart failure long-term registry investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19:1242\u201354.","journal-title":"Eur J Heart Fail."},{"key":"644_CR87","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ejhf.1492","volume":"21","author":"O Chioncel","year":"2019","unstructured":"Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al. ESC-EORP-HFA heart failure long-term registry investigators. Acute heart failure congestion and perfusion status \u2013 impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338\u201352.","journal-title":"Eur J Heart Fail"},{"key":"644_CR88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","volume":"258","author":"J Rubio-Gracia","year":"2018","unstructured":"Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185\u201391.","journal-title":"Int J Cardiol"},{"issue":"7","key":"644_CR89","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ejhf.1383","volume":"21","author":"P Pellicori","year":"2019","unstructured":"Pellicori P, Shah P, Cuthbert J, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 2019;21(7):904\u201316.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"644_CR90","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ejhf.129","volume":"16","author":"A Bottle","year":"2014","unstructured":"Bottle A, Aylin P, Bell D. Effect of the readmission primary diagnosis and time interval in heart failure patients: analysis of English administrative data. Eur J Heart Fail. 2014;16(8):846\u201353. https:\/\/doi.org\/10.1002\/ejhf.129.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"644_CR91","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cardfail.2014.12.008","volume":"21","author":"JS Krahnke","year":"2015","unstructured":"Krahnke JS, Abraham WT, Adamson PB, et al. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail. 2015;21(3):240\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2014.12.008.","journal-title":"J Card Fail"},{"issue":"4","key":"644_CR92","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejim.2013.02.013","volume":"24","author":"A Mor","year":"2013","unstructured":"Mor A, Thomsen RW, Ulrichsen SP, S\u00f8rensen HT. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. Eur J Intern Med. 2013;24(4):349\u201353.","journal-title":"Eur J Intern Med"},{"key":"644_CR93","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/eurjhf\/hft095","volume":"15","author":"F Zannad","year":"2013","unstructured":"Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082\u201394.","journal-title":"Eur J Heart Fail"},{"key":"644_CR94","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jchf.2019.09.007","volume":"8","author":"DJP Burns","year":"2020","unstructured":"Burns DJP, Arora J, Okunade O, Beltrame JF, Bernardez-Pereira S, Crespo-Leiro MG, et al. International consortium for health outcomes measurement (ICHOM): standardized patient-centered outcomes measurement set for heart failure patients. JACC Heart Fail. 2020;8:212\u201322. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.007. Important consensus document on patient related outcome measures in clinical trials of acute heart failure","journal-title":"JACC Heart Fail"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-024-00644-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T07:16:37Z","timestamp":1709882197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-024-00644-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s11897-024-00644-2","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"3 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}